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ABSTRACT Estrogens inf luence the differentiation and
maintenance of reproductive tissues and affect lipid metabo-
lism and bone remodeling. Two estrogen receptors (ERs) have
been identified to date, ERa and ERb. We previously gener-
ated and studied knockout mice lacking estrogen receptor a
and reported severe reproductive and behavioral phenotypes
including complete infertility of both male and female mice
and absence of breast tissue development. Here we describe
the generation of mice lacking estrogen receptor b (ERb
2y2) by insertion of a neomycin resistance gene into exon 3
of the coding gene by using homologous recombination in
embryonic stem cells. Mice lacking this receptor develop
normally and are indistinguishable grossly and histologically
as young adults from their littermates. RNA analysis and
immunocytochemistry show that tissues from ERb 2y2 mice
lack normal ERb RNA and protein. Breeding experiments
with young, sexually mature females show that they are fertile
and exhibit normal sexual behavior, but have fewer and
smaller litters than wild-type mice. Superovulation experi-
ments indicate that this reduction in fertility is the result of
reduced ovarian efficiency. The mutant females have normal
breast development and lactate normally. Young, sexually
mature male mice show no overt abnormalities and reproduce
normally. Older mutant males display signs of prostate and
bladder hyperplasia. Our results indicate that ERb is essen-
tial for normal ovulation efficiency but is not essential for
female or male sexual differentiation, fertility, or lactation.
Future experiments are required to determine the role of ERb
in bone and cardiovascular homeostasis.
Estrogens are critical to the functioning and maintenance of a
diverse array of tissues and physiological systems in mammals.
The actions of estrogen on such classical targets as the
reproductive tract, gonads, mammary tissue, and hypothalam-
icypituitary axis have been well characterized. A role in
nonreproductive tissues, such as maintenance of bone mineral
density and cardiovascular health in women, also has been
described (1, 2). The physiological responses to estrogen are
known to be mediated within specific tissues by at least two
estrogen receptors (ERs), ERa and ERb (3–5). The ERs are
a class I member of the nuclear hormone receptor family and
act as ligand-activated nuclear transcription factors (6). Studies
of the receptors’ tissue distribution and expression pattern
indicate that ERa has a broad expression pattern, whereas
ERb has a more focused pattern with high levels in the ovary,
prostate, epididymis, lung, and hypothalamus (7, 8). However,
the exact physiological responses attributable to each receptor
are unknown. We previously described the pleiotropic effects
of disruption of the ERa gene in ERa knockout mice
(aERKO), including absence of breast development in females
and infertility caused by reproductive tract and gonadal and
behavioral abnormalities in both sexes (9–13). Here, we de-
scribe the generation of mice homozygous for a disruption of
the ERb gene; initial characterizations indicate that the ERb
2y2 mice exhibit phenotypes that are distinct from those of
the aERKO mice.
MATERIALS AND METHODS
Disruption of the ERb Gene. Genomic P1 clones of the
mouse ERb gene from a 129ySvJ library were isolated by
Genome Systems (St. Louis) using primers and probes sup-
plied by us. Sequence analysis confirmed the validity of the
clones. A targeting construct (Fig. 1) was generated that
included 1.3 kb and 7.4 kb of genomic sequence as the 59 and
39 homology regions. A copy of the neomycin-resistance gene
(Neo) driven by a phosphoglucokinase promoter was inserted
in the reverse orientation into the PstI site in exon 3. The
targeting construct was linearized at the indicated NotI site and
introduced into the BK4 subline of the E14TG2a strain 129
embryonic stem (ES) cell line as described (14). Screening for
correctly targeted ES cells was accomplished by using PCR
(15), which gave a 1,479-bp band with a primer from intron 2
(59-GTGATGAGCTGAGGTGGTGCTT-39) and a primer
from the 39 end of the Neo (59-GCAGCCTCTGTTCCA-
CATACAC-39). Targeted ES cells were confirmed by using
Southern blot analysis with EcoRI-digested ES cell genomic
DNA and a probe specific to exon 2; the unmodified ERb gene
gives a 12-kb band, whereas the disrupted ERb gene gives a
5.4-kb band. Genotyping of tail DNA was accomplished by
using PCR with the intron 2 primer, the Neo primer, and a
third primer from exon 3 (59-CATCCTTCACAGGACCAGA-
CAC-39); a 1,435-bp band (intron 2 and exon 3 primers) is
amplified for homozygous wild-type (1y1) mice, a 1,479-bp
band (intron 2 and Neo primers) for homozygous mutant
(2y2) mice, and both bands for heterozygous (1y2) mice.
ERb mRNA Analysis. Tissue was removed from animals
immediately after sacrifice, snap-frozen, and stored at 270°C
until further processing. RNA was extracted by using TRIzol
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(GIBCOyBRL) reagent according to the manufacturer’s pro-
tocol. Reverse-transcriptase generation of cDNA was per-
formed on 1 mg of total RNA by using GeneAmp RNA PCR
reagents (Perkin–Elmer) with random hexamers according to
the manufacturer’s protocol in a final volume of 25 ml.
Subsequent PCR analysis was carried out on 5 ml of the cDNA,
and the products were analyzed by electrophoresis on a 1.5%
agarose gel. Two primers (59-GCCAATCATCGCTTCTC-
TAT-39 and 59-CCCTCTTTGCTCTTACTGTCCTCT-39) (4)
were used to generate a wild-type product of 1,291 bp. Primers
specific for the mouse b-actin cDNA (CLONTECH) were
used as a positive control and amplified a fragment of 540 bp.
The reverse transcription–PCR (RT-PCR) products were
cloned and sequenced by using primers specific to the vector
and the ERb cDNA.
Immunocytochemistry. Adult wild-type and ERb 2y2 fe-
males were sacrificed, and the ovaries were removed to 4%
buffered formalin at 4°C. The tissue was processed for immu-
nostaining by using the avidin–biotin peroxidase method as
described (16). The primary antiserum was specific for the
C-terminal amino acid residues 467–485 of the rat ERb
(Affinity Bioreagents, Golden, CO). Preabsorbed ERb anti-
serum was prepared by incubating 1 ml of the antiserum with
20 mg of peptide for 24 hr at 4°C. The secondary antibody was
biotin-labeled goat-antirabbit IgG. The final signal was gen-
erated with avidin–biotin peroxidase and diaminobenzidine
(BioGenex Laboratories, San Ramon, CA). The sections were
counterstained with hematoxylin.
Fertility Tests. For evaluation of female fertility, known
fertile males were placed with 4- to 6-week-old wild-type or
ERb 2y2 females for 8 weeks and then removed. Cages were
monitored daily, and for an additional 23 days, and presence
of seminal plugs, and number and size of litters were recorded.
To evaluate male fertility, 6-week-old ERb 2y2 males were
placed with known fertile females for 6 weeks, and the same
parameters were monitored.
Superovulation and Oocyte Quantitation. Wild-type, het-
erozygous, and ERb 2y2 female littermates 25–31 days old
were treated s.c. with 5 units of pregnant mare serum gonad-
otropin followed by 5 units of human chorionic gonadotropin
48–52 hr later. Animals were sacrificed 12–16 hr after the
second injection, the ovaries and oviduct were removed, the
oocyteycumulus mass was surgically extracted from the ovi-
duct, and oocytes were counted after hyaluronidase disasso-
ciation from the surrounding cumulus.
RESULTS
Targeted Disruption of the ERb Gene and Generation of
Mice. The targeting construct illustrated in Fig. 1 was used to
disrupt the ERb gene in ES cells. Of 83 cell lines doubly
resistant to G418 and ganciclovir, 14 were positive for targeting
as judged by using PCR and 7 were characterized by using
Southern blot analysis. All gave the expected wild-type 12-kb
band and a 5.4-kb band indicative of correct targeting. One of
these cell lines was injected into blastocysts and yielded two
male chimeras that when mated to C57BLy6J females trans-
mitted the strain 129 genome to their wild-type and heterozy-
gous-mutant F1 offspring. Intercrossing the F1 heterozygotes
FIG. 1. Targeted disruption of the ERb gene. (Top) The unmod-
ified genomic locus showing exons 2–4. The probe used for Southern
blots is labeled above exon 2. The small arrows indicate the positions
of primers. Restriction enzyme sites are EcoRI, BglII, and PstI,
designated by E, B, and P. (Middle) The targeting plasmid with the left
(1.3-kb) and right (7.4-kb) regions of homology. The Neo insertion site
is indicated. NotI (N) was used to linearize the plasmid. Homologous
recombination is indicated by the large Xs. (B) shows the BglII lost in
the construct. (Bottom) The targeted allele with the Neo gene inserted
into exon 3. Note the additional EcoRI site introduced during the
targeting. Mouse genomic DNA is shown as a thick line, the inserted
Neo sequences as a thinner line, and the plasmid vector as a zig-zag
line.
FIG. 2. RT-PCR for ERb mRNA in 1y1 and 2y2 tissues. (A) Gel electrophoresis of the products. The arrowheads indicate the bands
corresponding to full-length ERb mRNA and the b-actin control mRNA. The marker is labeled m. A lane loaded with PCR product in the absence
of reverse transcriptase is labeled ‘‘2RT’’. (B) Diagrammatic representation of the RT-PCR products (see text) from wild-type and mutant mRNA
(ERb-KO1, ERb-KO2, and ERb-KO3) derived by using the primers indicated by the black arrows. The top line (Protein) shows the domains of
the protein corresponding to the exons 1–9. AyB, N-terminal domain; C, DNA-binding domain; D, hinge domain; and EyF, ligand-binding domain.
The site of the Neo gene insertion is indicated by the open arrow.
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yielded F2 progeny including 122 ERb 1y1 (64 female, 58
male), 217 1y2 (109 female, 108 male), and 97 2y2 (50
female, 47 male), in agreement with Mendelian expectations
(x2, P 5 0.25) and a normal sex ratio.
RT-PCR Analysis of the Disrupted ERb Gene. The targeting
construct was designed so that the Neo insert would introduce
stop codons into exon 3 (resulting in premature termination of
translation of the ERb mRNA) and prevent the formation of
full-length functional ERb polypeptide. However, it also was
expected that some alternate RNA splicing might occur and
result in the formation of shorter forms of the ERb mRNA.
We therefore carried out RT-PCR analysis with ovarian and
prostate RNA from wild-type and mutant animals. The ex-
pected 1,291-bp product was obtained with RNA from wild-
type ovary and prostate. No 1,291-bp product was detected in
either of these same tissues from ERb 2y2 mice, although
small amounts of shorter PCR products were detected with
RNA from their ovaries. Three of these shorter forms (Fig. 2)
were cloned and sequenced: ERb-KO1 (4 clones), ERb-KO2 (4
clones), and ERb-KO3 (1 clone). ERb-KO1 and ERb-KO2,
1,149 bp and 1,095 bp in length, respectively, lack the disrupted
exon 3; both lead to a translational frameshift and the gener-
ation of multiple stop codons in exon 4; they differ by a 54-bp
insertion equivalent to a natural ERb mRNA variant that has
been described in the rat (17). The ERb-KO3 (979 bp in length)
lacks exons 3 and 4 of the ERb mRNA, and preserves the
reading frame, but would yield a polypeptide lacking the
residues known to function in DNA binding. We conclude that
the ERb 2y2 animals do not synthesize any mRNA coding for
the normal ERb polypeptide.
Ovarian Histology and Function in the ERb 2y2 Females.
Ovaries from young adult (7–9 weeks old) wild-type and ERb
2y2 females were examined for indications of function. Fig.
3 A and B show representative sections of an ovary from an
FIG. 3. Histology and ERb immunocytochemistry in wild-type and ERb 2y2 ovary. Hematoxylin-stained sections of adult wild-type (A) and
ERb 2y2 (B) ovary at 340 magnification; the arrows indicate mature follicles. (C) Immunocytochemistry of wild-type ovary with an antiserum
against ERb; o, oocyte within the follicle. (D) Immunocytochemistry of wild-type ovary with the antiserum preabsorbed with immunogenic ERb
peptide. (E) Immunocytochemistry of adult ERb 2y2 ovary with the ERb antiserum. Histologic sections of a representative ovary from an
immature wild-type female (F) and from an immature ERb 2y2 female (G), both after superovulation; several unruptured preovulatory follicles
in G are indicated by solid arrows. Corpora lutea (cl) are indicated in F and G by open arrows.
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adult wild-type and from an ERb 2y2 female. In both ovaries,
follicles are seen at various stages of development ranging from
primordial to fully developed with a clearly defined antrum.
There are indications of more early atretic follicles and fewer
corpora lutea in the ERb 2y2 ovary compared with the
wild-type ovary, suggesting partial arrest of follicular devel-
opment and less frequent follicular maturation.
Immunocytochemistry for the ERb protein (Fig. 3C) shows
clearly detectable expression of ERb in the granulosa cells of
maturing wild-type follicles, with the highest levels appearing
in granulosa cells lining the basement membrane of the follicle.
Fig. 3D shows the absence of signal in wild-type follicles with
antiserum preabsorbed with the antigenic peptide, thereby
establishing the specificity of the assay. Fig. 3E shows immu-
nostaining for ERb with ovary from an adult ERb 2y2
female; no specific staining is visible.
Reproductive Consequences of Lacking ERb. In a contin-
uous mating study, F2 ERb 2y2 females had significantly
fewer litters (P , 0.05) than F2 wild-type females (Table 1),
and the number of pups per litter was likewise significantly
lower (P , 0.001). Thus, the ERb 2y2 females exhibit
reduced fertility. Two of the tested ERb 2y2 females had no
litters despite the detection of vaginal plugs on multiple
occasions, suggesting that the infertility was not caused by any
impairment of sexual behavior. Young homozygous mutant
females (7–9 weeks) lacking ERb have normal mammary
histology and appear to lactate effectively, as judged by normal
nursing behavior and growth of their pups.
Males lacking ERb are normally fertile, as judged by test
matings with known fertile F1 females during which they
produced litters every 21 days, with an average litter size of
10.2 pups per litter.
In light of the breeding results indicating a reduced fertility
in the ERb 2y2 females, additional experiments to assess
ovarian function were carried out. Immature (25–31 days) ERb
2y2 females and their wild-type littermates were hormonally
stimulated (superovulated), and the oocyte yield per animal
was determined. The results of three independent trials with
animals of all three ERb genotypes are shown in Table 2. The
wild-type and heterozygous females exhibited an average yield
of 33.7 6 4.8 and 52.5 6 5.7 oocytes per female, with the oocyte
count from the heterozygotes being significantly greater than
wild type (P , 0.05). The ERb 2y2 females ovulated less
efficiently, yielding 6.0 6 1.5 oocytes per female (P , 0.001),
with 2 of 11 animals tested yielding no detectable ova. In
addition, the cumulus mass surrounding the ovulated follicles
from the ERb 2y2 females was composed of fewer cells when
compared with those from wild-type and ERb 1y2 mice. The
histology of the wild-type and ERb 2y2 ovaries from these
superovulation experiments are illustrated in Fig. 3 F and G.
In comparison with wild-type mice, the ovary from the ERb
2y2 mice shows a large number of mature oocytes (solid
arrows), indicating an intact response to pregnant mare serum
gonadotropin. However, there are fewer corpora lutea (open
arrows) in the ovaries of the stimulated ERb 2y2 ovary than
in the wild-type ovary, suggesting that some follicles failed to
fully respond and discharge their oocytes in response to the
ovulatory surge of hCG.
Male Urogenital Tract. High levels of ERb have been
reported in the male urogenital tract [especially in the prostate
and epididymis (7, 8, 18)]. Histological analysis of these tissues
from 2- to 3-month-old ERb 2y2 males showed no marked
abnormalities when compared with age-matched wild-type
littermates. However, older ERb 2y2 males exhibited indi-
cations of epithelial hyperplasia in the prostatic collecting
ducts as well as the bladder wall (data not shown).
DISCUSSION
Several recent discoveries and developments, including the
generation of aERKO (9) and aromatase knockout (ArKO)
mice (19), have changed our understanding of estrogen action
and have offered new insights into the mechanisms by which
endogenous estrogens and exogenous estrogenic and anties-
trogenic compounds exert their effects. The mouse models
have been complemented by the discovery of a human male
lacking functional ERa (20) and of human males and females
with mutations of the aromatase gene (21, 22). However, the
discovery of a second estrogen receptor, ERb, has introduced
a new level of uncertainty in our understanding of the mech-
anisms and role of estrogen and raises the possibility that the
two receptors have different actions. In the aERKO mice,
some estrogenic effects are preserved in tissues such as the
brain (23), cardiovascular system (24), and uterus (25), sug-
gesting that in these tissues ERb may mediate the effects of
estrogens. Here we have described the generation and initial
characterization of a mouse homozygous for a targeted dis-
ruption of the ERb gene, which in combination with the
models described above, should prove useful in further dis-
secting the roles of the individual estrogen receptors.
Breeding of mice heterozygous for the ERb gene disruption
yielded ERb 2y2 progeny in expected Mendelian proportions
and with normal sex ratios. The ERb 2y2 mice survive to
adulthood and do not exhibit any obvious abnormalities.
Assays for ERb mRNA demonstrate the lack of wild-type ERb
transcripts but indicate the presence of very small amounts of
three distinct splicing variants. Sequencing clones correspond-
ing to these variants showed that two of them not only are
missing sequences that encode the essential first zinc finger of
the DNA-binding domain but also cause a frameshift that
would result in a shortened form of the ERb protein. The third
and least common variant retains the normal translational
reading frame but would be missing the entire functional
portion of the DNA-binding domain, thought to be critical to
the function of nuclear steroid receptors (26). Thus the ERb
2y2 mutant animals lack any means of synthesizing normal
ERb. Immunocytochemistry employing an antibody specific
for the C-terminal amino acids of rat ERb confirms this
conclusion by demonstrating the absence of detectable ERb
protein in the ovaries of the ERb 2y2 mice compared with the
strong staining observed in the granulosa cells of the wild-type
ovary.
The role of estrogens in male reproduction is complex.
Previous studies have shown that male mice lacking ERa are
completely infertile (10, 12), whereas male mice lacking aro-
matase are fully fertile (16). In the present work, we found that
male mice lacking ERb are fully fertile. We conclude that
ERa, but not aromatase or ERb, are essential for normal male
fertility. Nevertheless, we have observed indications of age-
related abnormalities in the male urogenital tract—specifically
Table 1. Testing of female fertility
Female





1y1 6 17 150 2.8 6 0.4 8.8 6 2.5
2y2 11 19 59 1.7 6 1.0* 3.1 6 1.8**
Results are presented as mean 6 SD. p, P , 0.05 vs. 1y1, Student’s
two-tailed t-test. pp, P , 0.001 vs. 1y1, Student’s two-tailed t-test.




1y1 10 33.7 6 4.8 9–57
1y2 11 52.5 6 5.7* 20–77
2y2 11 6.0 6 1.5** 0–13
Results are presented as means 6 SD. p, P , 0.05 vs. 1y1, Student’s
two-tailed t-test. pp, P , 0.001 vs. 1y1, Student’s two-tailed t-test.
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in the prostate and bladder—but a more complete analysis of
the nature and incidence of this phenotype is needed.
Fertility in females is much more clearly dependent on a
multitude of estrogen actions mediated by both aromatase and
ERa, as demonstrated by the infertility of ArKO (16) and
aERKO (9, 11, 27) mice. Although the ERb 2y2 females are
not infertile, their fertility is compromised, as demonstrated by
the reduced number and size of litters compared with normally
fertile females in a continuous mating study. The occurrence
of successful pregnancies and seminal plugs in ERb 2y2
females that never produced a litter suggests, however, that the
sexual behaviors necessary for reproduction are intact in the
ERb 2y2 females. This is in marked contrast to the severe
deficit in sexual behavior described in the aERKO females (11,
28). Furthermore, the mammary glands from both virgin and
parous ERb 2y2 females did not reveal any notable differ-
ences from the wild-type mice.
The most likely cause of the subfertility in the ERb 2y2
females is a direct loss of ERb-mediated estrogen actions in the
ovary. Recent studies using in situ hybridization (3, 29), RNase
protection assay (8), and immunohistochemical data (15) and
the data we have presented here demonstrate that ERb is the
predominant form of ER in the ovary and that it is localized
to the granulosa cells of maturing follicles. Disruption of the
ERb gene, therefore, would be expected to have effects on
ovarian function and subsequent fertility in the female. The
general histology of ovaries from our adult ERb 2y2 mice
revealed a reduced number of corpora lutea, with indications
that follicular development may be partially arrested and that
completed follicular maturation occurs at a reduced fre-
quency. A more dramatic ovarian phenotype became evident
when the animals were stimulated to ovulate with exogenous
hormones. After superovulation, the number of oocytes re-
covered from the ERb 2y2 mice was less than 1y5 that seen
from wild-type or heterozygous mice. The number of oocytes
recovered from the heterozygous ERb 1y2 superovulated
females was greater than from wild-type females but was still
within the range of normal animals. The ovaries from the
superovulated ERb 2y2 females exhibited several mature but
unruptured follicles, resulting in trapped oocytes. The number
of corpora lutea detected in the ovary of ERb 2y2 animals
after superovulation was considerably lower than in the wild-
type animals. These results suggest an attenuated response to
the ovulatory hormone surge after human chorionic gonado-
tropin administration.
The conclusion we draw from the ovarian histology, the
continuous mating studies, and the superovulation experi-
ments is that the primary reproductive defect in the ERb 2y2
females is impaired ovarian function. Over two decades ago,
Richards (30) identified specific estradiol-binding sites in the
nuclei of granulosa cells that now appear to be most likely
caused by ERb rather than ERa. The ability of estradiol—
through an appropriate receptor—to enhance follicular re-
sponsiveness to gonadotropins also has long been known.
Thus, several studies have described estradiol effects in the
ovary, including an increase in granulosa cell growth and
number (31–33), increased synthesis of granulosa cell insulin-
like growth factor 1 (34), maintenance of follicle-stimulating
hormone receptor (35), induction of luteinizing hormone
receptor (36, 37), augmentation of aromatase activity and
subsequent estradiol production (38), and attenuation of gran-
ulosa cell apoptosis (39). The abnormalities we have observed
in the ERb 2y2 ovary (decreased rates of spontaneous
ovulation, increased atresia, decreased cellular mass of the
oocyte cumulus, and an inadequate response to exogenous
hormones) may well be the result of a loss of one or more of
the previously described estrogen actions.
Similar ovarian phenotypes have been reported in mice with
a disruption of the progesterone receptor gene (40), the cell
cycle-regulating cyclin-D2 gene (41), or the cyclooxygenase-2
gene (42). All have ovulatory defects. The ovarian phenotype
of the ERb 2y2 female is somewhat similar to that of the
ArKO female, which shows a complete termination of follicu-
logenesis at the preovulatory stage (16). However, the ovarian
phenotype of the ERb 2y2 female is markedly less severe
than that of the completely infertile aERKO female, in which
follicular arrest is complete and occurs at stages earlier than in
the ERb 2y2 ovary (10, 43). Furthermore, the enlarged and
hemorrhagic cystic follicles that are a hallmark of the aERKO
ovary are not present in the ERb 2y2 ovaries, indicating
separate mechanisms behind the phenotypes in the two mu-
tants. Studies of aERKO (44) and ArKO mice (16) show that
estrogen action via ERa is critical for the proper regulation of
gonadotropin synthesis and secretion in the hypothalamicy
pituitary system. However, because ERb is normally present in
the hypothalamus (8, 45), some disturbance in the normal
action of estrogen in the hypothalamicypituitary system of the
ERb 2y2 mice cannot be ruled out at this time.
Breast development and function is not compromised by
absence of ERb as judged by normal mammary histology and
lactation. In contrast, female mice lacking aromatase (16) or
ERa (10) show absence of breast tissue development beyond
that of prepubertal females. We conclude that estrogen acting
through ERa, but not through ERb, is essential for normal
breast development and function.
In summary, ERb 2y2 mice of both sexes appear to develop
normally and survive to adulthood. The urogenital tract
structures of both sexes undergo normal prenatal develop-
ment, although initial studies of the prostate and bladder of
older ERb 2y2 males indicate some abnormal hyperplasia.
Female mice lacking ERb have normal breast histology and
function but reduced fertility, with the predominating factors
apparently originating in the ovary. The similarities and dif-
ferences that we have noted between the previously described
aERKO and ArKO mice and ERb 2y2 mice emphasize the
complexity of the estrogen signaling system and its diverse
physiological roles. Future work is needed to determine the
effects of a lack of ERb in aging animals, particularly in
relation to the cardiovascular system and bone homeostasis.
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